PD-1/PD-L1
Gli inibitori di PD-1/PD-L1 sono inibitori del checkpoint immunitario che bloccano l'interazione tra la proteina di morte cellulare programmata 1 (PD-1) sui linfociti T e il suo ligando PD-L1 sulle cellule tumorali. Questa interazione sopprime normalmente la risposta immunitaria e permette alle cellule tumorali di sfuggire al riconoscimento immunitario. Inibendo PD-1/PD-L1, questi inibitori potenziano la capacità del sistema immunitario di riconoscere e distruggere le cellule tumorali, inducendo apoptosi e regressione tumorale. Gli inibitori di PD-1/PD-L1 sono fondamentali nella ricerca sull'immunoterapia e nel trattamento del cancro. Presso CymitQuimica, offriamo una gamma di inibitori di PD-1/PD-L1 di alta qualità per supportare la tua ricerca in immuno-oncologia, apoptosi e terapia del cancro.
Trovati 137 prodotti di "PD-1/PD-L1"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Sintilimab
CAS:Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.
Purezza:> 95%Colore e forma:LiquidPeso molecolare:144.04 kDaAUNP-12 acetate
AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in additionFormula:C144H230N40O50Purezza:95.07%Colore e forma:SolidPeso molecolare:3321.61Zimberelimab
CAS:Zimberelimab (GLS-010) is a humanized antibody targeting PD-1, with anticancer activity.Purezza:95%Colore e forma:LiquidPeso molecolare:146.54 kDaDurvalumab
CAS:Durvalumab is a humanized antibody for cancer, inhibiting PD-L1/PD-1 and CD80 interactions at very low concentrations.Purezza:95% - 97.2% (SDS-PAGE); 95.3% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:146.03 kDaBudigalimab
CAS:Budigalimab (ABBV 181) is a humanized monoclonal antibody targeting PD-1 with potential antitumor activity.
Purezza:97% (SDS-PAGE); 98.8% (SEC-HPLC) - 97% (SDS-PAGE); 98.8% (SEC-HPLC)Colore e forma:LiquidTislelizumab
CAS:Tislelizumab, a PD-1 receptor monoclonal antibody, reduces Fcγ interaction and T cell clearance in advanced squamous NSCLC research.Purezza:95.07%Colore e forma:LiquidEzabenlimab
CAS:Ezabenlimab (BI-754091) is an anti-PD-1 mAb, Kd 6 nM, blocks PD-1/PD-Ls, boosts T-cell IFN-γ, inhibits tumors in vivo.Purezza:99.1% (SDS-PAGE); 96.9% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.9% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:145.21 kDaBMS-1001 hydrochloride
CAS:BMS-1001 hydrochloride is an orally active inhibitor of human PD-1/PD-L1 immune checkpoint with low-toxicity in cells.BMS-1001 alleviates the inhibitory effectFormula:C35H35ClN2O7Purezza:97.36%Colore e forma:SolidPeso molecolare:631.11Ref: TM-T10565
1mg52,00€5mg120,00€10mg187,00€25mg380,00€50mg612,00€100mg973,00€200mg1.305,00€1mL*10mM (DMSO)169,00€Dostarlimab
CAS:Dostarlimab (TSR-042) is an immune checkpoint inhibitor targeting PD-1, blocking its interaction with its ligands PD-L1 and PD-L2.Purezza:>95%Colore e forma:LiquidPeso molecolare:144.18 kDaSpartalizumab
CAS:"Spartalizumab (PDR001), a humanized IgG4 monoclonal antibody, targets PD-1 to inhibit PD-L1/L2 interactions, useful in ATC research."Purezza:SDS-PAGE:95.2%;SEC-HPLC:96.3%Colore e forma:LiquidPeso molecolare:145.74 kDaPenpulimab
CAS:Penpulimab is a monoclonal antibody targeting PD-1 with antitumor activity, used in studies of pancreatic cancer.Purezza:96.8% (SEC-HPLC) - 96.8% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:145.14 kDaPD-1/PD-L1 inhibitory peptide C8
PD-1/PD-L1 inhibitory peptide C8 disrupts the PD-1/PD-L1 interaction, leading to the activation of CD8+ and CD4+ T cells and an increase in IFN-γ secretion. In mouse models, PD-1/PD-L1 inhibitory peptide C8 has demonstrated antitumor activity.Formula:C51H72N14O14S2Colore e forma:SolidPeso molecolare:1169.33PROTAC PD-1/PD-L1 degrader-1
CAS:PROTAC PD-1/PD-L1 degrader-1, a Cereblon-based inhibitor, blocks PD-1/PD-L1 with 39.2 nM IC50, boosting immune response and reducing PD-L1 via lysosomes.Formula:C59H58ClN7O11Purezza:99.07%Colore e forma:SolidPeso molecolare:1076.59CAY10678
CAS:CAY10678 is an mPGES-1 inhibitor that inhibits PD-1.CAY10678 reduces collagen deposition and T-cell depletion, and may be used to study melanoma.CASHIPSFormula:C23H34N4OPurezza:99.66%Colore e forma:SolidPeso molecolare:382.54PD-1/PD-L1-IN-31
PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral bloodFormula:C24H24ClFN2O3Purezza:98%Colore e forma:SolidPeso molecolare:442.912-Methylbiphenyl-oxadiazole-NH-Ph-CHO
CAS:2-Methylbiphenyl-oxadiazole-NH-Ph-CHO functions as a PD-L1 ligand for AUTACPD-L1degrader-3. It is also applicable in the synthesis of AUTAC.Formula:C22H17N3O2Colore e forma:SolidPeso molecolare:355.39PD-1/PD-L1-IN-32
PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM.Purezza:98%Colore e forma:Odour SolidPD-L1/VISTA-IN-2
PD-L1/VISTA-IN-2 (Compound S8) is an orally active dual inhibitor targeting PD-L1 and VISTA, with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. This compound can activate the tumor immune microenvironment, exerting anticancer effects.Formula:C22H22N2O3Colore e forma:SolidPeso molecolare:362.42Ledostomig
CAS:Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody that targets human neurotensin receptor type 5 (NTS5) and programmed death-1 (PD-1). It shows potential for research in various cancer types.Colore e forma:LiquidMoflerafusp alfa
CAS:Moflerafusp alfa is a fusion protein that targets the human signal-regulatory protein alpha (SIRPα) variant V2 D1 domain and human programmed death-ligand 1 (PD-L1). It shows potential for research in various cancer treatments.Colore e forma:LiquidZeluvalimab
CAS:Zeluvalimab (AMG-404) is a monoclonal antibody designed to target the PD-1 receptor, and is utilized in cancer research [1].Colore e forma:LiquidFinotonlimab
Finotonlimab (SCT-I10A), a humanized IgG PD-1 monoclonal antibody, shows potential in the research of solid tumors or lymphomas [1].Colore e forma:Odour LiquidManelimab
CAS:Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 ( PD-L1 ) [1] .Colore e forma:LiquidARB-272572 hydrochloride
CAS:ARB-272572 hydrochloride is a PD-L1 inhibitor that inhibits PD-1/PD-L1 cell signaling by inducing PD-L1 protein homology interactions.Formula:C32H36N6O4·xClHPurezza:99.38%Colore e forma:SoildPeso molecolare:568.68(Free base）Lorigerlimab
CAS:Lorigerlimab (MGD019) is a bispecific IgG4 DART that blocks PD-1/CTLA-4, enhancing T-cells for mCRPC research.Colore e forma:LiquidIMMH 010 maleate
CAS:IMMH 010 maleate (YPD-30 maleate) is a programmed cell death ligand 1 inhibitor used in the study of neurological disorders and advanced malignant solid tumors.Formula:C36H36BrClN2O9Colore e forma:SoildPeso molecolare:756.04PD-1/PD-L1-IN-50
Compound LG-12, known chemically as PD-1/PD-L1-IN-50, is an inhibitor of PD-1/PD-L1. It enhances the secretion of IFN-γ, promotes the activation of CD8+ T cells, and activates T cell-mediated anti-tumor immunity.Colore e forma:Odour SolidIzuralimab
CAS:Izuralimab is a bispecific IgG1 antibody that targets both the inducible T-cell costimulator (ICOS/CD278) and PD-1 [1].Colore e forma:LiquidPD-1/PD-L1-IN-51
PD-1/PD-L1-IN-51 (Compound III-4) is an inhibitor of PD-1/PD-L1 (IC50: hPD-L1 at 2.9 nM). It binds directly to PD-L1, blocking the interaction between PD-1 and PD-L1, and enhancing the release of IFN-γ. Additionally, PD-1/PD-L1-IN-51 exhibits antitumor activity.Colore e forma:Odour SolidLodapolimab
CAS:Lodapolimab (LY3300054) is an IgGλ anti- PD-1 monoclonal antibody [1] .Colore e forma:LiquidLon-TK
Lon-TK is a glycolysis inhibitor of LTB, linked with a linker conjugate. LTB is an intelligent responsive prodrug, comprised of Lonidamine (Lon) and a PD-L1 inhibitor (BMS-1), which are connected through a thioketal linkage. It effectively inhibits glycolytic metabolism in tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK holds potential for use in photodynamic-enhanced immunotherapy research.Formula:C24H28Cl2N2O3S2Colore e forma:SolidPeso molecolare:527.53Opucolimab
CAS:Opucolimab is a human antibody targeting PD-L1, used in advanced solid tumor research and antibody-drug conjugate synthesis.Colore e forma:LiquidBetifisolimab
CAS:Betifisolimab (MSB-2311) is a humanized antibody targeting PD-L1 for solid tumors and blood cancer research.Colore e forma:LiquidLP23
LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/JurkatFormula:C27H27N3O5SPurezza:98%Colore e forma:SolidPeso molecolare:505.59Sudubrilimab
Sudubrilimab (HS636) is an IgG1-κ monoclonal antibody targeting PDL1, fused with TGFBR2-ECD to block PD-1/PDL1 and TGF-β in tumors.Colore e forma:Odour LiquidD5B
D5B is an effective and selective PD-L1 inhibitor that has been modified with DBCO. It degrades PD-L1 in 4T1 and B16-F10 tumor cells with EC50 values of 5.4 μM and 6.2 μM, respectively. D5B can block the PD-L1/PD-1 interaction and exhibits antitumor activity.Formula:C58H66N2O12Colore e forma:SolidPeso molecolare:983.15Pimivalimab
CAS:Pimivalimab (JTX-4014), a PD-1 inhibitor, is utilized in solid tumor research [1].Colore e forma:LiquidPD-1/PD-L1-IN-52
PD-1/PD-L1-IN-52 (Compound Ⅲ-5) is an orally active inhibitor of PD-1/PD-L1 interaction, exhibiting an IC50 of 109.9 nM. It demonstrates antitumor activity in a C57BL/6 mouse model of MC38 colon carcinoma cells expressing human PD-1, achieving a tumor growth inhibition (TGI) rate of 49.6%.Colore e forma:Odour SolidSotiburafusp alfa
CAS:Sotiburafusp alfa is a humanized bispecific fusion protein comprising a VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) connectedPurezza:98%Colore e forma:SolidBalstilimab
CAS:Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1 [1] .Colore e forma:LiquidIparomlimab
CAS:Iparomlimab: anti-PD-1 IgG4κ antibody, targets PSB103 γ4/κ-chains, forms dimers, used in cancer research.Colore e forma:LiquidPD-1/PD-L1-IN-9
CAS:PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction.Formula:C22H24N2O2Purezza:99.92%Colore e forma:SolidPeso molecolare:348.44Ref: TM-T9651
1mg57,00€2mg85,00€5mg127,00€10mg178,00€25mg298,00€50mg405,00€100mg535,00€500mg1.063,00€1mL*10mM (DMSO)140,00€TPP-1 TFA
TPP-1 TFA is a high-affinity PD-L1 inhibitor (KD=95nM) that boosts T-cell function to curb tumor growth.Formula:C109H151F3N34O34S2Colore e forma:SolidPeso molecolare:2602.69PD-1/PD-L1-IN-48
PD-1/PD-L1-IN-48 (compound HD10) is an effective inhibitor of the PD-1/PD-L1 interaction, exhibiting an IC50 of 3.1 nM. It plays a vital role in cancer research.Colore e forma:Odour SolidHuman PD-L1 inhibitor I
CAS:Human PD-L1 inhibitor I, a peptide, blocks PD-L1/PD-1 interaction with 3.39 μM affinity.Formula:C110H152N26O32Colore e forma:SolidPeso molecolare:2350.576BMSpep-57
CAS:BMSpep-57: Macrocyclic peptide, inhibits PD-1/PD-L1, IC50=7.68 nM, binds PD-L1 (Kd=19 nM/MST, 19.88 nM/SPR), boosts T cell IL-2 in PBMCs.Formula:C89H126N24O19SColore e forma:SolidPeso molecolare:1868.2Human PD-L1 inhibitor II
CAS:Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Formula:C103H151N25O30Colore e forma:SolidPeso molecolare:2219.486LTB
LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1/PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).Formula:C53H59Cl2N3O7S2Colore e forma:SolidPeso molecolare:985.09PD-L1 inhibitory peptide
CAS:PD-L1inhibitory peptide is an inhibitor peptide that targets the programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it lifts immune suppression and restores the anti-tumor activity of T cells. PD-L1inhibitory peptide holds promise for use in tumor research.Formula:C96H135N21O23SColore e forma:SolidPeso molecolare:1983.29Volrustomig
CAS:Volrustomig is a bi-engineered fragment crystallizable (Fc) domain, a monovalent bispecific IgG1 monoclonal antibody targeting the key immune checkpoint receptors PD-1 and CTLA-4. It boosts T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. Molecular weight: 146.77 kDa.Colore e forma:LiquidHuman PD-L1 inhibitor IV
CAS:PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.Formula:C80H113N25O27Colore e forma:SolidPeso molecolare:1856.932Human PD-L1 inhibitor III
CAS:Human PD-L1 inhibitor III is a human PD-L1 inhibitor.Formula:C97H155N29O29SColore e forma:SolidPeso molecolare:2223.54PD-L1-IN-5
PD-L1-IN-5 (X22) is an orally active PD-L1 inhibitor with an IC50 of 785.6 nM, demonstrating antitumor activity in vivo.
PD-1/PD-L1-IN-39
PD-1/PD-L1-IN-39 (X 14) is an orally active PD-1/PD-L1 inhibitor with an IC50 value of 15.73 nM. It exhibits strong binding affinity to human and mouse PD-L1, with KD values of 14.62 and 392 nM, respectively. PD-1/PD-L1-IN-39 also demonstrates antitumor activity.Formula:C23H20ClFN2O3Peso molecolare:426.11465PROTAC PD-L1 degrader-1
PROTACPD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with significant PD-L1 protein degradation capacity. It demonstrates strong PD-L1 degradation activity in 4T1 cells, with a DC50 of 0.609 μM. This compound is applicable to breast cancer research.OPBP-1
OPBP-1 is a D-peptide developed through phage display screening, molecular docking, and molecular dynamics simulations. It exhibits high stability, strong antitumor activity, and oral bioavailability. OPBP-1 selectively binds to the PD-L1 protein, significantly blocking the interaction between PD-1 and PD-L1, which helps restore and enhance T lymphocyte function while reducing the proportion of myeloid-derived suppressor cells (MDSCs), counteracting tumor-induced immune evasion. OPBP-1 is applicable for research in cancer immunotherapy.
Formula:C64H92N20O19SPeso molecolare:1476.65683Camrelizumab
CAS:Camrelizumab (SHR-1210) is a human IgG4-κ monoclonal antibody with high affinity and directed against PD-1.Camrelizumab binds PD-1 with a binding affinity of up
Purezza:95% - 98.6%Colore e forma:LiquidPeso molecolare:143.7 kDaPidilizumab
CAS:Pidilizumab (CT-011), a humanized IgG1κ anti-PD-1 monoclonal antibody, serves as a DLL1 antagonist with potential applications in researching hematologicPurezza:98%Colore e forma:LiquidNofazinlimab
CAS:Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody for the study of unresectable hepatocellular carcinoma (uHCC).Purezza:98.6% (SDS-PAGE); 99.7% (SEC-HPLC) - 98.6% (SDS-PAGE); 99.7% (SEC-HPLC)Colore e forma:LiquidPeso molecolare:145.07 kDaLatikafusp
CAS:Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.Purezza:97.1% (SDS-PAGE); 97.4% (SEC-HPLC) - 97.1% (SDS-PAGE); 97.4% (SEC-HPLC)Colore e forma:LiquidBAT-1306
BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. It is applicable for research in colorectal cancer and solid tumors.Colore e forma:Odour LiquidPD-1/PD-L1-IN-40
PD-1/PD-L1-IN-40 (Compound EP16) is a PD-1/PD-L1 inhibitor. It effectively suppresses the production of exosomal PD-L1 with an IC50 of 0.108 μM. PD-1/PD-L1-IN-40 serves as a lead compound for the elimination of exosomal PD-L1 and is applicable in cancer research.Formula:C20H22N4O2Peso molecolare:350.17428PD-1/PD-L1-IN-49
PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1 with an IC50 of 77 nM. This compound can activate Jurkat T cells and effectively block the PD-1/PD-L1 immune checkpoint.Formula:C27H32N4O5Colore e forma:SolidPeso molecolare:492.5672-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc
2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc is the PD-L1 ligand-linker polymer of AUTACPD-L1degrader-3. It can be utilized in the synthesis of AUTAC.Formula:C35H45N5O6Colore e forma:SolidPeso molecolare:631.76AUNP-12
CAS:AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.Formula:C142H226N40O48Purezza:98%Colore e forma:SolidPeso molecolare:3261.55Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 (LALA-PG) Antibody (10F.9G2) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting and inhibiting mouse PD-L1/B7-H1.Colore e forma:Odour LiquidAM0001
AM0001 is a human monoclonal antibody (mAb) that targets PDCD1/PD-1/CD279. It is applicable in cancer research.Colore e forma:Odour LiquidGR-1405
GR-1405 is a human monoclonal antibody (mAb) that targets B7-H1/PD-L1/CD274. It enhances the antitumor immune response mediated by cytotoxic T lymphocytes (CTL) against tumor cells expressing PD-L1. GR-1405 is applicable in research related to lymphomas and solid tumors.Colore e forma:Odour LiquidRK-10
CAS:RK-10 is a peptide that binds to PD-L1. After being conjugated with Cy5 or Biotin, RK-10 can be used to identify PD-L1-expressing tumors through flow cytometry or immunohistochemistry. It is applicable for research in detecting cancers such as non-small cell lung cancer (NSCLC), breast cancer, squamous cell carcinoma, and melanoma.Formula:C105H176N28O36SColore e forma:SolidPeso molecolare:2438.75Enlonstobart
CAS:Enlonstobart is a humanized IgG4-κ monoclonal antibody targeting PDCD1, functioning as both an immunostimulant and antineoplastic agent [1].Colore e forma:LiquidPMT-O9-1A
PMT-O9-1A is an effective PD-L1 degrader that reduces PD-L1 protein expression and exhibits cytotoxic properties. Additionally, PMT-O9-1A possesses anticancer activity.Formula:C22H25ClN2O4Colore e forma:SolidPeso molecolare:416.90Lipustobart
CAS:Lipustobart is an IgG4-kappa humanized monoclonal antibody targeting PDCD1 (programmed cell death 1, PD1, PD-1, CD279), with immunostimulant and antineoplasticPurezza:98%Colore e forma:LiquidSasanlimab
CAS:Sasanlimab (PF-06801591), a humanized IgG4-κ antibody, selectively targets PD-1 and is primarily produced in Chinese Hamster Ovary (CHO) cells [1].Purezza:98%Colore e forma:LiquidHuman membrane-bound PD-L1 polypeptide
CAS:Human membrane-bound PD-L1 polypeptide serves as an antigen for inducing the production of PD-L1 antibodies [1].
Formula:C85H140N26O36SPurezza:98%Colore e forma:SolidPeso molecolare:2134.24H-20
CAS:H-20 is a PD-1 agonist that reduces the required dosage of morphine for analgesia. It can be used in studies related to chronic pain.
Formula:C44H64N10O15Colore e forma:SolidPeso molecolare:973.037Asudemotide
CAS:Asudemotide is a bioactive chemical.Formula:C58H80N10O17Purezza:98%Colore e forma:SolidPeso molecolare:1189.31HX009
HX009 is a bispecific antibody that targets PD1 and CD47, though its binding to CD47 is attenuated. HX009 functions by blocking PD1/CD47 and can be utilized in research related to non-Hodgkin lymphoma (NHL).Colore e forma:Odour LiquidTQB-2858
TQB-2858 is a bifunctional fusion protein composed of an anti-PD-L1 monoclonal antibody fused with the extracellular domain of the TGF-β receptor. It exhibits high affinity for PD-L1, TGF-β1, and TGF-β3, and demonstrates a high target occupancy rate for PD-L1. TQB-2858 can be used in research on osteosarcoma and alveolar soft part sarcoma (ASPS).
Colore e forma:Odour LiquidGJ19
GJ19 is a PD-L1 inhibitor with an IC50 of 32.06 nM. It binds effectively to human and mouse PD-L1 proteins, exhibiting KD values of 171 nM and 290 nM, respectively. In a co-culture model of HepG2/hPD-L1 and Jurkat T/hPD-1 cells, GJ19 promotes HepG2 cell death in a concentration-dependent manner. In the B16-F10 melanoma mouse model, GJ19 demonstrates significant tumor growth inhibition. GJ19 is applicable in tumor immunotherapy research.Colore e forma:Odour SolidRTX-002
RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. This compound is applicable in the research of autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis.Colore e forma:Odour LiquidPacmilimab
CAS:Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.Purezza:98.8% (SDS-PAGE); 96.3% (SEC-HPLC) - 98.8% (SDS-PAGE); 96.3% (SEC-HPLC)Colore e forma:LiquidEciskafusp alfa
CAS:Eciskafusp alfa, a cis-targeted IL2v immunocytokine, acts on programmed cell death 1 (PDCD1, commonly known as PD-1), preferentially targeting antigen-specificPurezza:98%Colore e forma:Solid(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstratingFormula:C72H99F3N20O23Purezza:98%Colore e forma:SolidPeso molecolare:1669.67Acrixolimab
CAS:Acrixolimab is a humanized IgG4-κ monoclonal antibody that selectively targets PD-1 [1] [2].Purezza:98%Colore e forma:LiquidProlgolimab
CAS:Prolgolimab (BCD-100) is an anti-PD-1 antibody used in melanoma research.Purezza:>95%Colore e forma:LiquidPeso molecolare:146.28 kDaRetifanlimab
CAS:Retifanlimab (MGA-012) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Retifanlimab is used in studies of Merkel cell carcinoma.Purezza:98.56% (SEC-HPLC) - >95.0% (SDS-PAGE); 100% (SEC-HPLC)Colore e forma:LiquidDanburstotug
CAS:Danburstotug (IMC-001), an immunostimulant and antineoplastic [1], is a humanized IgG1-lambda monoclonal antibody targeting CD274 (PDL1, B7 homologue 1, B7H1).Purezza:98%Colore e forma:LiquidAnti-Mouse PD-L1 Antibody (10F.9G2)
Anti-Mouse PD-L1 Antibody (10F.9G2) is an IgG-class antibody against mouse PD-L1.Purezza:98.92% - >95.0% (SDS-PAGE); 0.996 (SEC-HPLC)Colore e forma:Odour LiquidAnti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)
Anti-MousePD-1(LALA-PG) Antibody (RMP1-14) is an IgG2a, κ antibody inhibitor derived from mice that targets and inhibits mouse PD-1.Colore e forma:Odour LiquidOpamtistomig
CAS:Opamtistomig is a humanized monoclonal antibody immunoglobulin (H-γ1-scFv-L-κ) dimer targeting human programmed death-ligand 1 (PD-L1), CD274, and tumor necrosis factor receptor superfamily member 9 (TNFRSF9). It is anticipated for use in research on various solid tumors and hematologic malignancies.
Colore e forma:LiquidN-deacetylated BMS-202
CAS:N-deacetylated BMS-202 is an inhibitor of PD-1/PD-L1 interaction with potential anticancer activity for cancer research.Formula:C23H27N3O2Purezza:98.13% - 98.13%Colore e forma:SolidPeso molecolare:377.48BMS-8
CAS:BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction (IC50: 7.2 μM) by binding directly to PD-L1 and inducing the formation of PD-L1 homodimers.Formula:C27H28BrNO3Purezza:98.88%Colore e forma:SolidPeso molecolare:494.42Ref: TM-T26859
1mg39,00€5mg84,00€10mg131,00€25mg235,00€50mg359,00€100mg533,00€200mg743,00€1mL*10mM (DMSO)90,00€BMS-1001
CAS:BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction(IC50 : 2.25 nM, in a homogenous time-resolved fluorescence binding assay).Formula:C35H34N2O7Purezza:98.43%Colore e forma:SolidPeso molecolare:594.7Ref: TM-T8470
1mg62,00€5mg131,00€10mg187,00€25mg316,00€50mg447,00€100mg620,00€200mg835,00€1mL*10mM (DMSO)182,00€BMS-1166
CAS:BMS-1166 is a potent PD-1/PD-L1 interaction inhibitor.
Formula:C36H33ClN2O7Purezza:99.22%Colore e forma:SolidPeso molecolare:641.11Nivolumab
CAS:Nivolumab is a monoclonal antibody, a humanized IgG4 antibody to PD-1. Nivolumab has antitumor activity. Cost-effective and quality-assured.Purezza:98% - 98%Colore e forma:LiquidPeso molecolare:143.62 kDaARB-272572
CAS:ARB-272572 is a PD-L1 signaling inhibitor that produces immunostimulatory activity in human primary cells.Formula:C32H36N6O4Purezza:97.36% - 98.07%Colore e forma:SolidPeso molecolare:568.67Ref: TM-T39914
1mg130,00€5mg311,00€10mg449,00€25mg752,00€50mg1.093,00€100mg1.568,00€200mg2.110,00€1mL*10mM (DMSO)373,00€Socazolimab
CAS:Socazolimab (ZKAB001) is a monoclonal antibody targeting PD-L1 with antitumor activity, used in studies of recurrent or metastatic cervical cancer.Purezza:95%Colore e forma:LiquidBMS-1166-N-piperidine-CO-N-piperazine dihydrochloride
CAS:BMS-1166-N-piperidine-CO-N-piperazine dihydrochloride is a resorcinol di-Ph ether scaffold-based programmed cell death-1 (PD-1)/programmed cell death ligand 1 (Formula:C41H45Cl3N4O5Purezza:98.94%Colore e forma:SoildPeso molecolare:780.18Envafolimab
CAS:Envafolimab (ASC 22) is a humanized antibody targeting PD-L1, with anticancer activity, blocking the PD-L1 and PD-1 interaction.Purezza:95%Colore e forma:LiquidPeso molecolare:80 kDaSugemalimab
CAS:Sugemalimab: human anti-PD-L1 IgG4 mAb with anticancer properties for non-small cell lung cancer.
Colore e forma:Liquid
